MAPT and Alzheimer disease: The inhibition of Sgk1 by WDR5-0103 treatment reduced hyperphosphorylated tau, restored glutamatergic synaptic function, and improved memory deficits in AD mice, highlighting its potential as a therapeutic target in AD [170].